Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study

Lutf, Abdo; Poil, Abdul Razzakh; Hammoudeh, Mohammed

doi:10.1111/1756-185x.12135

Cited by 17 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Badsha et al5 reported patients from the United Arab Emirates to have a mean DAS 28 of 5.2, and 12% of their patients were in the low disease activity or remission categories. In another regional study by Lutf et al,6 findings were different from our study in a heterogeneous group of patients with RA. Their mean DAS 28 was 2.85, 49% were in remission, and an additional 15% were in the low disease activity category 6…”

Section: Discussioncontrasting

confidence: 99%

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

Alawneh¹,

Khassawneh²,

Ayesh³

et al. 2014

TCRM

View full text Add to dashboard Cite

Treating rheumatoid arthritis (RA) to target is advocated using disease activity measures. The impact of RA on the general health status of affected patients in Jordan is not well described. This study reported the severity of RA in Jordan and its association with consequent disabilities and comorbidities. A cross-sectional, observational study was conducted at King Abdullah University Hospital in the north of Jordan. All patients who were diagnosed with RA were included. Patients’ demographics, comorbidities, disease activity score (DAS 28), and clinical disease activity index (CDAI) were collected. Both DAS 28 and CDAI were utilized to categorize RA disease activity. A total of 465 patients with RA were included: 82% were females; mean age ± standard deviation (SD) was 47.62±14.6 years; and mean disease duration ± SD was 6±4.45 years. The mean ± SD for the DAS 28 and CDAI was 5.1±1.5 and 23±14.2, respectively. According to the DAS 28, 51% of the patients were in the high disease activity category and only 5% were in remission. On the other hand, according to the CDAI, 44% were in the high disease activity category and only 1% were in remission. In Jordan, patients with RA have a high severe disease rate and a low remission rate. The disease is often progressive and associated with comorbidities that need to be managed.

show abstract

Section: Discussioncontrasting

confidence: 99%

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

Alawneh¹,

Khassawneh²,

Ayesh³

et al. 2014

TCRM

View full text Add to dashboard Cite

show abstract

“… 2 Patients in these countries are also often undertreated 5 , 16 and there is wide variation in treatment, with 5% of patients in the United Arab Emirates (UAE) and 29% in Qatar receiving a biologic, compared with over 40% of eligible patients in the USA. 19 In part, this can be attributed to the high socioeconomic burden of other more prevalent diseases in the Middle East and Arabian Gulf countries, such as diabetes. 15 Public awareness regarding RA is also generally low in the region, but data from the UAE show that the introduction of patient support groups and disease awareness campaigns are beginning to show an effect.…”

Section: Discussionmentioning

confidence: 99%

“… 5 , 15 In Qatar, the majority of patients receive conventional synthetic (cs) DMARDs, and 64% of patients seen in the clinic achieve LDA or remission. 19 Yet despite this move towards modern practice, RA patients often experience a delay in diagnosis: a recent study in Dubai found erosions in 55% of patients, suggesting a delay in diagnosis and management. 16 A review examining the use of the European League Against Rheumatism (EULAR) recommendations in this region found that there were barriers to implementation, mainly for those individual recommendations that advocated aggressive management, early use of intensive therapy and frequent monitoring.…”

Section: Introductionmentioning

confidence: 99%

An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions

et al. 2017

Self Cite

View full text Add to dashboard Cite

ObjectiveThis study assessed the mode of application (oral, intravenous or subcutaneous (SC)) currently employed in the treatment of rheumatoid arthritis (RA) in patients from Qatar in comparison with patients’ individual preferences for the mode of application of their treatment.MethodsThis study included 294 RA patients visiting three clinics at the main referral hospital in Qatar who were interviewed using a standard questionnaire to determine their preference of mode of application for their disease-modifying antirheumatic drug (DMARD) treatment in relation to their currently employed mode of application.ResultsThe majority of patients were female (76%), and 93% of male patients and 61% of female patients in the study clinics were of a nationality other than Qatari. The highest patient preference recorded was for an oral therapy (69%), compared with injection (23%) and intravenous (8%) therapy. In total, 85% of patients expressed a preference to remain on oral therapy compared with 63% and 58% of intravenous and SC injection patients indicating a preference to remain on their current method of administration.ConclusionsThis high preference for oral therapies highlights the considerable need for incorporation of new oral targeted synthetic DMARD therapies into clinical practice within the region.

show abstract

“…In a multicenter cross-sectional study of RA in Chinese patients receiving csDMARDs, bDMARDs, and/or glucocorticoids, Wang et al found the remission rate to be 8.6 % (DAS28), 8.2 % (CDAI), 8.4 % (SDAI), and 6.8 % (Boolean) [27]. In Qatari, the remission rate of patients with RA receiving bDMARDs and/or csDMARDs was 49 % by DAS28 score [28]. In the QUEST-RA study including patients with RA from 25 mostly European countries, remission rate was 13.8 % and 19.6 % by CDAI and DAS28, respectively [29].…”

Section: Discussionmentioning

confidence: 99%

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study

Liu

et al. 2016

Clin Rheumatol

View full text Add to dashboard Cite

The aims of this study are to characterize the biological disease-modifying antirheumatic drug (bDMARD) usage patterns in real-life and examine the remission rate of rheumatoid arthritis (RA) patients receiving bDMARDs in routine clinical practice in China. Consenting RA patients (≥18 years) from 15 teaching hospitals and receiving marketed bDMARDs were included. In total, 802 patients (81.3 % women, 49.0 ± 13.9 years) were included; 89.5 % were receiving a combination of bDMARDs and conventional synthetic DMARDs (csDMARDS), whereas 10.5 % were receiving bDMARD monotherapy. Etanercept (including Enbrel® and local brand Yi Sai Pu® and Qiangke®), tocilizumab, adalimumab, and infliximab were used by 66.6 %, 17.0 %, 7.5 %, and 6.6 % patients, respectively. Etanercept was used at a mean weekly dose of 38.2 ± 15.6 mg for 25.5 ± 47.0 weeks and tocilizumab at 94.5 ± 21.9 mg for 4.7 ± 7.5 weeks. Overall rate of remission was 12.6 %, 5.4 % , and 3.5 % based on DAS28, CDAI, and SDAI scores, respectively. Compared with patients receiving bDMARDs for <3 months, those receiving bDMARDs for ≥3 months exhibited significantly lower DAS28 scores (p < 0.0001), and a significantly higher proportion of patients who received bDMARDs for ≥12 months achieved the treatment goal (remission or low disease activity, 62.5 % vs. 18.3 %, p < 0.0001). Patients receiving combination therapy with csDMARDs exhibited lower DAS28 scores than patients receiving bDMARD monotherapy (4.3 vs. 4.8, p = 0.011). This large-scale real-world study showed that bDMARD usage patterns in routine clinical practice in China were in accordance with international guidelines for RA management despite the short treatment duration. Longer duration of bDMARD usage and combination therapy showed a favored outcome of RA.

show abstract

Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study

Abstract: Sixty-four percent of rheumatoid arthritis patients in Qatar were in remission or had low disease activity while the remaining 36% had active disease and among these patients 29% were on biologics.

Cited by 17 publications

References 8 publications

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

Rheumatoid arthritis in Jordan: a cross sectional study of disease severity and associated comorbidities

An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions

The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study

Contact Info

Product

Resources

About